Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin)

被引:27
作者
Nachbaur, D [1 ]
Herold, M [1 ]
Gächter, A [1 ]
Niederwieser, D [1 ]
机构
[1] Univ Innsbruck Hosp, Dept Internal Med, Div Clin Immunobiol & Bone Marrow Transplantat, A-6020 Innsbruck, Austria
关键词
D O I
10.1046/j.1365-2567.1998.00495.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mode of action of intravenous immunoglobulins (IVIG) in autoimmune and immunoregulatory disorders is still poorly understood. In vitro, direct effects of IVIG on cytokine release and on cytokine receptors have been described, as well as naturally occurring, neutralizing anticytokine antibodies. The aim of our study was to investigate whether the enrichment in IgM and IgA would have any impact on the in vitro immunomodilatory capacity of MG. The preparation tested (Pentaglobin) contains 76% IgG and 12% IgM and IgA, respectively. We could demonstrate a significant inhibition of alloantigen-induced proliferation in the mixed lymphocyte reaction (MLR) even at a Pentaglobin concentration of 10 mg/ml. About 10-fold higher concentrations of standard 7S IVIG containing only trace amounts of IgM and IgA were necessary to achieve equivalent suppression of the alloimmune response. Similarly, phytohaemagglutinin (PHA)induced lymphocyte proliferation was more effectively inhibited by Pentaglobin than by standard 7S IVIG. Cytokine analyses in culture supernatants of MLR provide evidence that Pentaglobin not only modulates interleukin-2 (IL-2), which has already been observed with standard 7S MG, but, moreover, modulates interferon-gamma production with a subsequent impact on monocyte-derived tumour necrosis factor-alpha and IL-6 release. Based on these results we conclude that in vitro the IgM- and IgA-enriched Pentaglobin has a more potent immunomodulatory capacity than conventionally used standard 7S IVIG.
引用
收藏
页码:279 / 283
页数:5
相关论文
共 27 条
[1]   ANTI-CYTOKINE NATURE OF NATURAL HUMAN-IMMUNOGLOBULIN - ONE POSSIBLE MECHANISM OF THE CLINICAL EFFECT OF INTRAVENOUS IMMUNOGLOBULIN THERAPY [J].
ABE, Y ;
HORIUCHI, A ;
MIYAKE, M ;
KIMURA, S .
IMMUNOLOGICAL REVIEWS, 1994, 139 :5-19
[2]   SUPPRESSION OF CYTOKINE-DEPENDENT HUMAN T-CELL PROLIFERATION BY INTRAVENOUS IMMUNOGLOBULIN [J].
AMRAN, D ;
RENZ, H ;
LACK, G ;
BRADLEY, K ;
GELFAND, EW .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 73 (02) :180-186
[3]   Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes macrophages [J].
Andersson, J ;
SkansenSaphir, U ;
Sparrelid, E ;
Andersson, U .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 :10-20
[4]   POOLED HUMAN-IGG MODULATES CYTOKINE PRODUCTION IN LYMPHOCYTES AND MONOCYTES [J].
ANDERSSON, U ;
BJORK, L ;
SKANSENSAPHIR, U ;
ANDERSSON, J .
IMMUNOLOGICAL REVIEWS, 1994, 139 :21-42
[5]  
DICHTELMULLER H, 1987, DRUG RES, V37, P1273
[6]   IS THERE A ROLE FOR INTERLEUKIN-1 BLOCKADE IN INTRAVENOUS IMMUNOGLOBULIN THERAPY [J].
DINARELLO, CA .
IMMUNOLOGICAL REVIEWS, 1994, 139 :173-188
[7]  
DWYER JM, 1992, NEW ENGL J MED, V326, P107
[8]  
HOLLER E, 1990, BLOOD, V75, P1011
[9]  
HUBER C, 1981, J IMMUNOL, V127, P726
[10]   Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease [J].
Hurez, V ;
Kazatchkine, MD ;
Vassilev, T ;
Ramanathan, S ;
Pashov, A ;
Basuyaux, B ;
deKozak, Y ;
Bellon, B ;
Kaveri, SV .
BLOOD, 1997, 90 (10) :4004-4013